|Table of Contents|

Research progress of cGAS-STING signaling pathway in tumor immunotherapy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 05
Page:
883-888
Research Field:
Publishing date:

Info

Title:
Research progress of cGAS-STING signaling pathway in tumor immunotherapy
Author(s):
YANG Yuanyuan; DUAN Weiming
Department of Oncology Medicine，the First Affiliated Hospital of Soochow University，Jiangsu Suzhou 215006，China.
Keywords:
cGAS-STING; tumor; STING agonist; immunotherapy
PACS:
R730.51
DOI:
10.3969/j.issn.1672-4992.2025.05.025
Abstract:
The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling pathway,as an important pathway of the innate immune system,promotes the production of type I interferon (IFN-I) through the recognition of DNA from specific sources,thereby activating a wide range of immune cells in the tumor microenvironment and exerting a potent anti-tumor immune function.Considerable research progress has been made in tumor immunotherapy strategies based on the biological functions of the cGAS-STING pathway,and emerging cancer therapeutic approaches such as cGAS-independent STING agonist therapy.This paper reviews the multifaceted roles of the cGAS-STING pathway in tumor biology and the potential breakthroughs it brings to tumor immunotherapy,increasing the understanding of the mechanisms underlying the cGAS-STING pathway in tumor immunity and providing an important theoretical framework for the development of more effective immunotherapeutic strategies.

References:

［1］ LIU Z,WANG D,ZHANG J,et al.cGAS-STING signaling in the tumor microenvironment［J］.Cancer Lett,2023,577:216409.
［2］ ZIERHUT C,FUNABIKI H.Regulation and consequences of cGAS activation by self-DNA ［J］.Trends Cell Biol,2020,30(8):594-605.
［3］ SHANG G,ZHANG C,CHEN ZJ,et al.Cryo-EM structures of STING reveal its mechanism of activation by cyclic GMP-AMP ［J］.Nature,2019,567(7748):389-393.
［4］ ZHANG C,SHANG G,GUI X,et al.Structural basis of STING binding with and phosphorylation by TBK1 ［J］.Nature,2019,567(7748):394-398.
［5］ GUO Q,CHEN X,CHEN J,et al.STING promotes senescence,apoptosis,and extracellular matrix degradation in osteoarthritis via the NF-kappaB signaling pathway ［J］.Cell Death Dis,2021,12(1):13.
［6］ CHABANON RM,ROUANNE M,LORD CJ,et al.Targeting the DNA damage response in immuno-oncology:developments and opportunities ［J］.Nat Rev Cancer,2021,21(11):701-717.
［7］ REISLANDER T,GROELLY FJ,TARSOUNAS M.DNA damage and cancer immunotherapy:A STING in the tale ［J］.Mol Cell,2020,80(1):21-28.
［8］ CAMPISI M,SUNDARARAMAN SK,SHELTON SE,et al.Tumor-derived cGAMP regulates activation of the vasculature ［J］.Front Immunol,2020,11:2090.
［9］ GUI X,YANG H,LI T,et al.Autophagy induction via STING trafficking is a primordial function of the cGAS pathway ［J］.Nature,2019,567(7747):262-266.
［10］ CHEON H,HOLVEY-BATES EG,MCGRAIL DJ,et al.PD-L1 sustains chronic,cancer cell-intrinsic responses to type I interferon,enhancing resistance to DNA damage ［J］.Proc Natl Acad Sci USA,2021,118(47):e2112258118.
［11］ ANTONANGELI F,NATALINI A,GARASSINO MC,et al.Regulation of PD-L1 expression by NF-kappaB in cancer ［J］.Front Immunol,2020,11:584626.
［12］ GAO Y,LI Y,LIN Z,et al.Ataxia telangiectasia mutated kinase inhibition promotes irradiation-induced PD-L1 expression in tumour-associated macrophages through IFN-I/JAK signalling pathway ［J］.Immunology,2023,168(2):346-361.
［13］ QUANEY MJ,PRITZL CJ,LUERA D,et al.STING controls T cell memory fitness during infection through T cell-intrinsic and IDO-dependent mechanisms ［J］.Proc Natl Acad Sci USA,2023,120(3):e2205049120.
［14］ LI S,MIRLEKAR B,JOHNSON BM,et al.STING-induced regulatory B cells compromise NK function in cancer immunity ［J］.Nature,2022,610(7931):373-380.
［15］ STOROZYNSKY Q,HITT MM.The impact of radiation-induced DNA damage on cGAS-STING-mediated immune responses to cancer ［J］.Int J Mol Sci,2020,21(22):8877.
［16］ HE Y,YANG Y,HUANG W,et al.Manganese facilitated cGAS-STING-IFNI pathway activation induced by ionizing radiation in glioma cells ［J］.Int J Radiat Biol,2023,99(12):1890-1907.
［17］ DIAMOND JM,VANPOUILLE-BOX C,SPADA S,et al.Exosomes shuttle TREX1-sensitive IFN-stimulatory dsDNA from irradiated cancer cells to DCs ［J］.Cancer Immunol Res,2018,6(8):910-920.
［18］ FLOYD W,PIERPOINT M,SU C,et al.Atrx deletion impairs CGAS/STING signaling and increases sarcoma response to radiation and oncolytic herpesvirus ［J］.J Clin Invest,2023,133(13):e149310.
［19］ HU Y,MANASRAH BK,MCGREGOR SM,et al.Paclitaxel induces micronucleation and activates pro-inflammatory cGAS-STING signaling in triple-negative breast cancer ［J］.Mol Cancer Ther,2021,20(12):2553-2567.
［20］ WANG Z,CHEN J,HU J,et al.cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity ［J］.J Clin Invest,2019,129(11):4850-4862.
［21］ FU G,WU Y,ZHAO G,et al.Activation of cGAS-STING signal to inhibit the proliferation of bladder cancer:the immune effect of cisplatin ［J］.Cells,2022,11(19):3011.
［22］ DING L,KIM HJ,WANG Q,et al.PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer ［J］.Cell Rep,2018,25(11):2972-2980 e2975.
［23］ WAYNE J,BROOKS T,LANDRAS A,et al.Targeting DNA damage response pathways to activate the STING innate immune signaling pathway in human cancer cells ［J］.FEBS J,2021,288(15):4507-4540.
［24］ SEN T,RODRIGUEZ BL,CHEN L,et al.Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer ［J］.Cancer Discov,2019,9(5):646-661.
［25］ BEJARANO L,JORDAO MJC,JOYCE JA.Therapeutic targeting of the tumor microenvironment ［J］.Cancer Discov,2021,11(4):933-959.
［26］ FLOOD BA,HIGGS EF,LI S,et al.STING pathway agonism as a cancer therapeutic ［J］.Immunol Rev,2019,290(1):24-38.
［27］ WANG H,HU S,CHEN X,et al.cGAS is essential for the antitumor effect of immune checkpoint blockade ［J］.Proc Natl Acad Sci USA,2017,114(7):1637-1642.
［28］ KORNEENKO TV,PESTOV NB,NEVZOROV IA,et al.At the crossroads of the cGAS-cGAMP-STING pathway and the DNA damage response:implications for cancer progression and treatment ［J］.Pharmaceuticals (Basel),2023,16(12):1675.
［29］ YI M,LI T,NIU M,et al.Exploiting innate immunity for cancer immunotherapy ［J］.Mol Cancer,2023,22(1):187.
［30］ LU X,WANG X,CHENG H,et al.Anti-triple-negative breast cancer metastasis efficacy and molecular mechanism of the STING agonist for innate immune pathway ［J］.Ann Med,2023,55(1):2210845.
［31］ VASIYANI H,SHINDE A,ROY M,et al.The analog of cGAMP,c-di-AMP,activates STING mediated cell death pathway in estrogen-receptor negative breast cancer cells ［J］.Apoptosis,2021,26(5-6):293-306.
［32］ SIVICK KE,DESBIEN AL,GLICKMAN LH,et al.Magnitude of therapeutic STING activation determines CD8(+) T cell-mediated anti-tumor immunity ［J］.Cell Rep,2018,25(11):3074-3085 e3075.
［33］ VYSKOCIL S,CARDIN D,CIAVARRI J,et al.Identification of novel carbocyclic pyrimidine cyclic dinucleotide STING agonists for antitumor immunotherapy using systemic intravenous route ［J］.J Med Chem,2021,64(10):6902-6923.
［34］ LUKE JJ,PIHA-PAUL SA,MEDINA T,et al.Phase I study of SYNB1891,an engineered E.coli nissle strain expressing STING agonist,with and without atezolizumab in advanced malignancies ［J］.Clin Cancer Res,2023,29(13):2435-2444.
［35］ WANG L,ZHANG S,HAN J,et al.Activation of STING pathway contributed to cisplatin-induced cardiac dysfunction via promoting the activation of TNF-alpha-AP-1 signal pathway ［J］.Front Pharmacol,2021,12:711238.
［36］ PAN BS,PERERA SA,PIESVAUX JA,et al.An orally available non-nucleotide STING agonist with antitumor activity ［J］.Science,2020,369(6506):eaba6098.
［37］ SONG C,LIU D,LIU S,et al.SHR1032,a novel STING agonist,stimulates anti-tumor immunity and directly induces AML apoptosis ［J］.Sci Rep,2022,12(1):8579.
［38］ ZHANG J,YU S,PENG Q,et al.Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies ［J］.Cancer Biol Med,2024,21(1):45-64.

Memo

Memo:
-
Last Update: 1900-01-01